Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors

Silence Therapeutics bolsters board

Silence Therapeutics has hired Stuart Collinson as a non-executive director as Simon Sturge resigns to take up other business commitments
Silence Therapeutics bolsters board
Experienced Collinson, 55, has held senior management roles at GlaxoWellcome, now GlaxoSmithKline and Baxter International...

Silence Therapeutics (LON:SLN) has hired Stuart Collinson as a non-executive director as Simon Sturge resigns to take up other business commitments.

Experienced Collinson, 55, has held senior management roles at GlaxoWellcome, now GlaxoSmithKline and Baxter International and was chairman, chief executive and president of previously listed Aurora Biosciences, which was acquired by Vertex Pharmaceuticals (NASDAQ:VRTX) in 2001.

He has held various positions in public and private life science companies in the US and Europe and is a partner of Forward Ventures, a biopharmaceutical venture capital fund.

Ali Mortazavi, the chief executive of Silence Therapeutics, said: "We are very pleased to welcome Stuart to our board, who brings with him extensive experience in the sector with a business development and M&A track record across the US and Europe."

Shares were unchanged at 137.875p.

Giles_55af4ddca6481.jpg
Why Invest In Silence Therapeutics plc? Read More Here

Register here to be notified of future SLN Company articles
View full SLN profile

Silence Therapeutics plc Timeline

Related Articles

inhaler.jpg
April 05 2016
If the market worked as perfectly as its more rabid advocates insist, we wouldn’t have attractive anomalies such as Synairgen..
Dendritic cells with T-lymphocytes
July 21 2016
With cases of skin cancer on the rise, Scancell's immunotherapy study data has come at the right time, but is it enough to offset the insecurity in the sector?
Knee surgery
July 13 2016
The treatment involves removing cellular material from animal and human tissue to leave a matrix which gives a framework for population by the patient’s own cells.

© Proactive Investors 2016

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.